Self-Monitoring Blood Glucose (SMBG) Devices Market (By Type: Blood Glucose Meter, Blood Glucose Test Strips, Blood Glucose Lancet, And Others; By Geography: North America, Europe, Asia-Pacific and RoW) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015 – 2024

September 2017 | 115 pages | ID: SF5EA52C58DEN
Variant Market Research

Abstracts

Self-Monitoring Blood Glucose (SMBG) Devices Market is estimated to reach $20 Billion by 2024; growing at a CAGR of 6.2% from 2016 to 2024. Self-Monitoring Blood Glucose (SMBG) device is a modern tool used for the management of diabetes mellitus. It enables testing of the concentration of glucose in the blood by smearing the blood on chemically active disposable test-strip. According to WHO, it was estimated that around 246 million adults were suffering from diabetes in 2007, and the number is expected to reach 380 million by 2025. SMBG is highly essential for people with diabetes in order to control the level of glycemic and prevent hypoglycemia. However, the frequency of monitoring the blood glucose level mar vary from person to person.

The global self-monitoring blood glucose devices is driven by factors such as rapid increase in the number of diabetic patients, declining price of these devices, reimbursements by insurance companies, and rising patient’s awareness. Though, tough competition from private label brands, and lack of awareness among patients would restrain the growth of the market. Additionally, new marketing strategies, and technological advancements could offer growth opportunities in the coming years.

The self-monitoring blood glucose devices market is segmented as type, and geography. Type is further bifurcated as blood glucose test strips, blood glucose meter, blood glucose lancet, and others.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is further bifurcated in U.S., Canada and Mexico whereas Europe consist of UK, Russia, Germany, France, Italy, Spain, and others. Asia-Pacific is segmented into India, China, Japan, and others while RoW is bifurcated into South America, Middle East and Africa.

The key market players include Arkray, Inc., B. Braun Melsungen AG, Bionime Corporation, F. Hoffmann-La Roche Ltd, Medtronic Public Limited, Bayer AG, Abbott Laboratories, Life Scan Inc.(J&J), Trividia Health Inc., and Dexcom Inc., among others.

The key takeaways from the report

• The report will provide detailed analysis of Global Self-Monitoring Blood Glucose (SMBG) Devices Market with respect to major segments such as type, and geography
• The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
• Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
• An exhaustive regional analysis of Global Self-Monitoring Blood Glucose (SMBG) Devices Market has been included in the report
• Profile of the key players in the Global Self-Monitoring Blood Glucose (SMBG) Devices Market will be provided, which include key financials, product & services, new developments and business strategies

Scope of Global Self-Monitoring Blood Glucose (SMBG) Devices Market

Type Segments

• Blood Glucose Test Strips
• Blood Glucose Meter
• Blood Glucose Lancet
• Other Types

Geographical Segments

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Russia
• Germany
• France
• Italy
• Spain
• Others
• Asia Pacific
• India
• China
• Japan
• Others
• RoW
• South America
• Middle East
• Africa

Contents

CHAPTER 1 PREFIX

1.1 Market Scope
1.2 Report Description
1.3 Research Methodology
  1.3.1 Primary Research
  1.3.2 Secondary Research
  1.3.3 In-house Data Modeling

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 MARKET OUTLINE

3.1 Market Inclination, Trend, Outlook and Viewpoint
3.2 Market Share Analysis: Company’s Competitive Scenario
3.3 Market Dynamics
  3.3.1 Drivers
    3.3.1.1 Impact Analysis
  3.3.2 Restraints
    3.3.2.1 Impact Analysis
  3.3.3 Opportunities

CHAPTER 4 SELF-MONITORING BLOOD GLUCOSE (SMBG) DEVICES MARKET BY TYPE: MARKET SIZE AND FORECAST, 2015 – 2024

4.1 Overview
4.2 Blood Glucose Meter
  4.2.1 Current Trend and Analysis
  4.2.2 Market Size and Forecast
4.3 Blood Glucose Test Strips
  4.3.1 Current Trend and Analysis
  4.3.2 Market Size and Forecast
4.4 Blood Glucose Lancet
  4.4.1 Current Trend and Analysis
  4.4.2 Market Size and Forecast
4.5 Other Types
  4.5.1 Current Trend and Analysis
  4.5.2 Market Size and Forecast

CHAPTER 5 SELF-MONITORING BLOOD GLUCOSE (SMBG) DEVICES MARKET BY GEOGRAPHY: MARKET SIZE AND FORECAST, 2015 – 2024

5.1 Overview
5.2 North America
  5.2.1 Current Trend and Analysis
  5.2.2 Market Size and Forecast
  5.2.3 US
    5.2.3.1 Market Size and Forecast
  5.2.4 Canada
    5.2.4.1 Market Size and Forecast
  5.2.5 Mexico
    5.2.5.1 Market Size and Forecast
5.3 Europe
  5.3.1 Current Trend and Analysis
  5.3.2 Market Size and Forecast
  5.3.3 Germany
    5.3.3.1 Market Size and Forecast
  5.3.4 France
    5.3.4.1 Market Size and Forecast
  5.3.5 United Kingdom
    5.3.5.1 Market Size and Forecast
  5.3.6 Italy
    5.3.6.1 Market Size and Forecast
  5.3.7 Russia
    5.3.7.1 Market Size and Forecast
  5.3.8 Spain
    5.3.8.1 Market Size and Forecast
  5.3.9 Others
    5.3.9.1 Market Size and Forecast
5.4 Asia-Pacific
  5.4.1 Current Trend and Analysis
  5.4.2 Market Size and Forecast
  5.4.3 China
    5.4.3.1 Market Size and Forecast
  5.4.4 India
    5.4.4.1 Market Size and Forecast
  5.4.5 Japan
    5.4.5.1 Market Size and Forecast
  5.4.6 Others
    5.4.6.1 Market Size and Forecast
5.5 RoW
  5.5.1 Current Trend and Analysis
  5.5.2 Market Size and Forecast
  5.5.3 Middle East
    5.5.3.1 Market Size and Forecast
  5.5.4 South America
    5.5.4.1 Market Size and Forecast
  5.5.5 Africa
    5.5.5.1 Market Size and Forecast

CHAPTER 6 COMPANY PROFILES

6.1 F. Hoffmann-La Roche Ltd
6.2 B. Braun Melsungen AG
6.3 Medtronic Public Limited
6.4 Abbott Laboratories
6.5 Bayer AG
6.6 Life Scan Inc.(J&J)
6.7 Arkray, Inc.
6.8 Trividia Health Inc.
6.9 Bionime Corporation
6.10 Dexcom Inc.